Wednesday, February 10, 2016

Catalent Pharma Solutions says it's selling its Philadelphia packaging operation

Catalent Pharma Solutions said in a statement that it recently signed a "definitive agreement" to sell its Northeast Philadelphia drug packaging plant and another in Woodstock, Ill., to Frazier Healthcare, a West Coast venture capital firm..

Catalent Pharma Solutions says it's selling its Philadelphia packaging operation


Catalent Pharma Solutions said in a statement that it recently signed a "definitive agreement" to sell its U.S. commercial packaging operations based in Northeast Philadelphia and Woodstock, Ill., to a company affiliated with Frazier Healthcare, which is a West Coast-based venture capital firm.

The Catalent statement said "the transaction is subject to certain closing conditions and is expected to close in the next few months."

Catalent is controlled by the Blackstone Group. Blackstone paid about $3.3 billion to Cardinal Health for Catalent in 2007.

Catalent's U.S. headquarter is in Somerset, N.J., but it has operations on five continents.

More coverage

The 427,908-square foot packaging plant on Red Lion Road in Northeast Philadelphia is the largest of the company's facilities, according to a filing with the Securities and Exchange Commission.

However, Catalent specifically said the separate Philadelphia facility that is in the clinical supply services division will not be sold, nor will the the Blow-Fill-Seal business in Woodstock. The announcement did not mention the Mount Laurel facility as being part of the sale.

Catalent said the sale does not involve any commercial packaging activity outside North America.

"Catalent’s decision to sell its U.S. commercial packaging operations is based on the company’s business strategy to focus on growing its world leading businesses in development solutions and advanced delivery technologies, clinical trial supplies, advanced blow/fill/seal aseptic delivery technology for respiratory, ophthalmic and other products, as well as offering integrated solutions for the development and supply of injectable biologics and complex pharmaceutical products," Catalent said in the statement.

Staff Writer
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy: comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
comments powered by Disqus
About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at or 215-854-4506.

David Sell Staff Writer
Also on
letter icon Newsletter